Pfizer (NYSE:PFE) Trading Up 1.2% - What's Next?

Key Points

• Pfizer's stock experienced a 1.2% increase, trading at $24.52 with a market capitalization of $139.38 billion.
• Analysts have revised their price targets for Pfizer, with estimates ranging from $25.00 to $32.00, and a consensus rating of "Hold."
• The company announced a quarterly dividend of $0.43, set to be paid on December 1st, reflecting a yield of 7.0%.

Pfizer Inc. (NYSE:PFE - Get Free Report) shares were up 1.2% during mid-day trading on Friday . The company traded as high as $24.53 and last traded at $24.52. Approximately 39,866,228 shares changed hands during mid-day trading, a decline of 15% from the average daily volume of 46,863,430 shares. The stock had previously closed at $24.23.

Analysts Set New Price Targets

A number of equities analysts have issued reports on PFE shares. Citigroup upped their target price on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. UBS Group reissued a "neutral" rating and issued a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Morgan Stanley decreased their price target on Pfizer from $33.00 to $32.00 and set an "equal weight" rating for the company in a research note on Friday, October 10th. Weiss Ratings reissued a "hold (c-)" rating on shares of Pfizer in a research note on Wednesday, October 8th. Finally, Wall Street Zen cut Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday, September 28th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $28.13.

Pfizer Stock Up 1.2%

The firm has a 50 day moving average of $24.89 and a 200 day moving average of $24.12. The firm has a market cap of $139.38 billion, a price-to-earnings ratio of 13.04, a PEG ratio of 0.81 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter last year, the firm posted $0.60 earnings per share. The firm's revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer's dividend payout ratio is presently 91.49%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. GKV Capital Management Co. Inc. bought a new position in Pfizer in the first quarter worth approximately $27,000. Curio Wealth LLC boosted its holdings in Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 1,098 shares in the last quarter. North Capital Inc. bought a new position in Pfizer in the first quarter worth approximately $28,000. Bayforest Capital Ltd bought a new position in shares of Pfizer in the first quarter valued at approximately $28,000. Finally, Harbor Asset Planning Inc. bought a new position in shares of Pfizer in the second quarter valued at approximately $29,000. Institutional investors own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.